Verastem, Inc.
NASDAQ:VSTMBiotechnology
-$0.00 today
- Market cap
- $933.77M
- Beta
- 0.27
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$1.97
Volume 2.87M
Average 2.58M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Verastem, Inc.
NASDAQ:VSTM
Intrinsic Alpha fair value
Locked
Current Price
$7.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +128.4% | +78.3% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +128.4% over three years. Forward estimates point to Revenue at +78.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Nuvation Bio Inc. NYSE:NUVB | $1.40B | $3.99 | Not rated | -12.8 | -18.75% |
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | $814.71M | $7.86 | Not rated | -6.7 | -32.77% |
Adlai Nortye Ltd. NASDAQ:ANL | $563.18M | $10.61 | Not rated | -3.0 | +503.82% |
C4 Therapeutics, Inc. NASDAQ:CCCC | $362.43M | $2.76 | Not rated | -4.9 | +2.02% |
Prelude Therapeutics Incorporated NASDAQ:PRLD | $275.32M | $3.45 | Not rated | -4.5 | +97.62% |
Immuneering Corporation NASDAQ:IMRX | $240.27M | $3.71 | Not rated | -3.6 | -51.61% |
BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT | $171.74M | $2.14 | Not rated | -1.5 | -85.61% |
Foghorn Therapeutics Inc. NASDAQ:FHTX | $124.12M | $2.07 | Not rated | -3.8 | -63.55% |
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | $62.14M | $1.45 | Not rated | -0.8 | -41.15% |
Cardiff Oncology, Inc. NASDAQ:CRDF | $56.49M | $0.73 | Not rated | -1.8 | -58.51% |
Continue the stock analysis
Jump to another research area for this company.